Sarepta Therapeutics, Inc. (SRPT)
NASDAQ: SRPT · Real-Time Price · USD
21.34
+0.39 (1.86%)
At close: Nov 28, 2025, 1:00 PM EST
21.33
-0.01 (-0.03%)
After-hours: Nov 28, 2025, 4:59 PM EST
Sarepta Therapeutics Revenue
Sarepta Therapeutics had revenue of $399.36M in the quarter ending September 30, 2025, a decrease of -14.52%. This brings the company's revenue in the last twelve months to $2.41B, up 47.15% year-over-year. In the year 2024, Sarepta Therapeutics had annual revenue of $1.90B with 52.97% growth.
Revenue (ttm)
$2.41B
Revenue Growth
+47.15%
P/S Ratio
0.87
Revenue / Employee
$1,759,267
Employees
1,372
Market Cap
2.24B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.90B | 658.64M | 52.97% |
| Dec 31, 2023 | 1.24B | 310.32M | 33.26% |
| Dec 31, 2022 | 933.01M | 231.13M | 32.93% |
| Dec 31, 2021 | 701.89M | 161.79M | 29.96% |
| Dec 31, 2020 | 540.10M | 159.27M | 41.82% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
SRPT News
- 3 days ago - Sarepta Secures FDA Nod For Elevidys Study To Reduce Liver Injury Risk - Benzinga
- 3 days ago - Sarepta Announces Approval to Begin ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne - Business Wire
- 4 days ago - Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics - Business Wire
- 4 days ago - Sarepta Provides Progress Update for SRP-1003, its Investigational siRNA treatment for Myotonic Dystrophy Type 1 - Business Wire
- 13 days ago - 2 Beaten-Down Stocks to Avoid Right Now - The Motley Fool
- 14 days ago - Sarepta Shares Jump After FDA Approves Updated Elevidys Label - Benzinga
- 14 days ago - Sarepta Announces FDA's Approval of Updated ELEVIDYS Prescribing Information - Business Wire
- 14 days ago - US FDA adds strongest warning to Sarepta gene therapy after fatal liver injuries - Reuters